Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Inflammation plays a major role in atherosclerosis. Pentraxin 3 (PTX3) a multifunctional pattern-recognition protein, is expressed in many tissues/cells, including innate immunity cells, endothelium and atherosclerotic plaques. Its role is controversial: it may exert protective cardiovascular effects and/or it may be an indicator of plaque vulnerability and future cardiovascular risk.
LDL-Apheresis removes apoB100-containing lipoproteins and it can prevent progression of coronary artery disease (CAD). LDL-Apheresis exerts non-lipidic beneficial effects on the procoagulatory state and on hemorheology. No data exist about the effects of LDL-Apheresis on plasma PTX3 levels.
Hypercholesterolemic patients with documented CAD, on chronic fortnightly LDL-apheresis treatment will be enrolled in this study.
Blood samples will be collected before and after a single LDL-Apheresis treatment to asses PTX3, HsCRP, IL6, IL10, Fibrinogen and lipid plasma levels.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Hypercholesterolemic patients | Hypercholesterolemic Patients with documented CAD and poor- or non responders or intolerant to pharmacological treatment (statins) on chronic LDL-apheresis treatment |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LDL-apheresis | Procedure | The acronym H.E.L.P. stands for Heparin-induced Extracorporeal Low-density-lipoprotein Precipitation. Antecubital veins served as blood access. The mean blood volume processed per session is of approximately 3000 ml. |
| Measure | Description | Time Frame |
|---|---|---|
| acute change in PTX3 plasma values | blood samples will be collected before and after a single LDL-apheresis treatment | before and at the end of one LDL-apheresis treatment (about 6 hours) |
| Measure | Description | Time Frame |
|---|---|---|
| acute change in hsCRP | blood samples will be collected before and after a single LDL-apheresis treatment | before and at the end of one LDL-apheresis treatment (about 6 hours) |
| acute change in IL6 and IL10 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Hypercholesterolemic patients with documented CAD, on cronic fortnightly HELP-apheresis treatment.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Enzo Bonora, Professor | Universita di Verona | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Endocrinologia e Malattie Metaboliche, Azienda Ospedaliera Universitaria Integrata Verona | Verona | Piazzale Stefani1 | 37126 | Italy |
Not provided
| ID | Term |
|---|---|
| D006937 | Hypercholesterolemia |
| D003324 | Coronary Artery Disease |
| ID | Term |
|---|---|
| D006949 | Hyperlipidemias |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
serum and plasma
|
blood samples will be collected before and after a single LDL-apheresis treatment
| before and at the end of one LDL-apheresis treatment (about 6 hours) |
| D009750 |
| Nutritional and Metabolic Diseases |
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |